Bank of New York Mellon Corp lifted its position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) by 3.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 218,118 shares of the medical instruments supplier’s stock after purchasing an additional 7,490 shares during the quarter. Bank of New York Mellon Corp owned about 1.13% of LeMaitre Vascular worth $8,161,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of LMAT. Rhumbline Advisers boosted its holdings in LeMaitre Vascular by 137.5% in the 3rd quarter. Rhumbline Advisers now owns 58,535 shares of the medical instruments supplier’s stock worth $2,190,000 after acquiring an additional 33,891 shares during the period. Advisor Group Inc. boosted its holdings in LeMaitre Vascular by 119.1% in the 3rd quarter. Advisor Group Inc. now owns 5,483 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 2,980 shares during the period. Municipal Employees Retirement System of Michigan boosted its holdings in LeMaitre Vascular by 800.3% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 26,470 shares of the medical instruments supplier’s stock worth $991,000 after acquiring an additional 23,530 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in LeMaitre Vascular by 97.6% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 7,405 shares of the medical instruments supplier’s stock worth $277,000 after acquiring an additional 3,657 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in LeMaitre Vascular by 17.1% in the 3rd quarter. Principal Financial Group Inc. now owns 119,887 shares of the medical instruments supplier’s stock worth $4,486,000 after acquiring an additional 17,480 shares during the period. Institutional investors and hedge funds own 69.24% of the company’s stock.

LeMaitre Vascular Inc (NASDAQ:LMAT) opened at $31.55 on Thursday. LeMaitre Vascular Inc has a 52-week low of $19.82 and a 52-week high of $39.88. The stock has a market capitalization of $600.17, a P/E ratio of 40.45, a price-to-earnings-growth ratio of 2.48 and a beta of 0.55.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.05. The company had revenue of $24.80 million for the quarter, compared to analyst estimates of $25.49 million. LeMaitre Vascular had a return on equity of 16.16% and a net margin of 15.81%. LeMaitre Vascular’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.17 EPS. research analysts predict that LeMaitre Vascular Inc will post 0.84 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 7th. Investors of record on Wednesday, November 22nd were given a dividend of $0.055 per share. This represents a $0.22 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend was Tuesday, November 21st. LeMaitre Vascular’s dividend payout ratio is currently 28.21%.

A number of brokerages have issued reports on LMAT. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 target price on the stock in a research report on Thursday. BidaskClub lowered LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Stifel Nicolaus reaffirmed a “buy” rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Canaccord Genuity cut their target price on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating on the stock in a research report on Friday, October 27th. Finally, Benchmark lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $32.20.

In related news, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the sale, the insider now directly owns 24,482 shares of the company’s stock, valued at approximately $786,851.48. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 23.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Bank of New York Mellon Corp Raises Stake in LeMaitre Vascular Inc (LMAT)” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://theolympiareport.com/2017/12/28/bank-of-new-york-mellon-corp-raises-stake-in-lemaitre-vascular-inc-lmat.html.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular Inc (NASDAQ:LMAT).

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.